Clinical Trials | November 15, 2023
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Phase 3 data expected in the second half of 2024
Phase 3 data expected in the second half of 2024
The company has raised US$4.5 million in funding for its AI operating system
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The companies plan to start a pivotal Phase 3 trial in the coming months
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Over 34 lakh children and 6 lakh pregnant women were administered vaccine doses during the first 2 rounds of IMI 5.0 campaign across the country
Two-year partnership focused on advocacy, education, and raising awareness of stroke as a global healthcare challenge
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
Subscribe To Our Newsletter & Stay Updated
